Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission - PubMed (original) (raw)

. 2011 Apr 6;3(77):77ra29.

doi: 10.1126/scitranslmed.3001888.

Erin Kahle, Jairam R Lingappa, Robert W Coombs, Sinead Delany-Moretlwe, Edith Nakku-Joloba, Nelly R Mugo, Anna Wald, Lawrence Corey, Deborah Donnell, Mary S Campbell, James I Mullins, Connie Celum; Partners in Prevention HSV/HIV Transmission Study Team

Collaborators, Affiliations

Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission

Jared M Baeten et al. Sci Transl Med. 2011.

Abstract

High plasma HIV-1 RNA concentrations are associated with an increased risk of HIV-1 transmission. Although plasma and genital HIV-1 RNA concentrations are correlated, no study has evaluated the relationship between genital HIV-1 RNA and the risk of heterosexual HIV-1 transmission. In a prospective study of 2521 African HIV-1 serodiscordant couples, we assessed genital HIV-1 RNA quantity and HIV-1 transmission risk. HIV-1 transmission linkage was established within the partnership by viral sequence analysis. We tested endocervical samples from 1805 women, including 46 who transmitted HIV-1 to their partner, and semen samples from 716 men, including 32 who transmitted HIV-1 to their partner. There was a correlation between genital and plasma HIV-1 RNA concentrations: For endocervical swabs, Spearman's rank correlation coefficient ρ was 0.56, and for semen, ρ was 0.55. Each 1.0 log(10) increase in genital HIV-1 RNA was associated with a 2.20-fold (for endocervical swabs: 95% confidence interval, 1.60 to 3.04) and a 1.79-fold (for semen: 95% confidence interval, 1.30 to 2.47) increased risk of HIV-1 transmission. Genital HIV-1 RNA independently predicted HIV-1 transmission risk after adjusting for plasma HIV-1 quantity (hazard ratio, 1.67 for endocervical swabs and 1.68 for semen). Seven female-to-male and four male-to-female HIV-1 transmissions (incidence <1% per year) occurred from persons with undetectable genital HIV-1 RNA, but in all 11 cases, plasma HIV-1 RNA was detected. Thus, higher genital HIV-1 RNA concentrations are associated with greater risk of heterosexual HIV-1 transmission, and this effect was independent of plasma HIV-1 concentrations. These data suggest that HIV-1 RNA in genital secretions could be used as a marker of HIV-1 sexual transmission risk.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JRL is a member of the scientific advisory board of Prosetta Bioconformatics, Inc; CC has served as a paid scientific advisor to the research advisory boards of Merck and Gilead. The other authors report no competing interests.

Figures

Figure 1

Figure 1. Step-wise association between genital and plasma HIV-1 RNAquantity and HIV-1 transmission risk

HIV-1 transmission incidence detailed within categories of quantity of HIV-1 RNA for a) female-to-male and b) male-to-female HIV-1 transmission. HIV-1 incidence for each HIV-1 RNA quantity category (undetectable, <3, 3–4, 4–5, and ≥5 log10) is presented, for both genital HIV-1 RNA and plasma HIV-1 RNA. A step-wise relationship between HIV-1 quantity and HIV-1 transmission incidence was observed, for both genital and plasma HIV-1 quantity. The lower limit of quantification was 240 copies per mL for blood and seminal plasma and 240 copies/swab for endocervical samples.

Similar articles

Cited by

References

    1. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr HIV Res. 2003;1:69–86. - PubMed
    1. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003;17:455–480. - PubMed
    1. Anderson BL, Cu-Uvin S. Determinants of HIV shedding in the lower genital tract of women. Curr Infect Dis Rep. 2008;10:505–511. - PubMed
    1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1 Rakai Project Study Group. N Engl J Med. 2000;342:921–929. - PubMed
    1. Chuachoowong R, Shaffer N, Siriwasin W, Chaisilwattana P, Young NL, Mock PA, Chearskul S, Waranawat N, Chaowanachan T, Karon J, Simonds RJ, Mastro TD. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 2000;181:99–106. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources